Alto Neuroscience, Net Worth
Alto Neuroscience, Net Worth Breakdown | ANRO |
Alto Neuroscience, Net Worth Analysis
Alto Neuroscience,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Alto Neuroscience,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Alto Neuroscience,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Alto Neuroscience,'s net worth analysis. One common approach is to calculate Alto Neuroscience,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Alto Neuroscience,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Alto Neuroscience,'s net worth. This approach calculates the present value of Alto Neuroscience,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Alto Neuroscience,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Alto Neuroscience,'s net worth. This involves comparing Alto Neuroscience,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Alto Neuroscience,'s net worth relative to its peers.
To determine if Alto Neuroscience, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alto Neuroscience,'s net worth research are outlined below:
| Alto Neuroscience, generated a negative expected return over the last 90 days | |
| Alto Neuroscience, has high historical volatility and very poor performance | |
| Net Loss for the year was (36.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience, generates negative cash flow from operations | |
| Alto Neuroscience, has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: 17,721 Shares in Alto Neuroscience, Inc. Acquired by Skandinaviska Enskilda Banken AB publ |
Alto Neuroscience, Target Price Consensus
Alto target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Alto Neuroscience,'s target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Alto analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Alto stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Alto Neuroscience,, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAlto Neuroscience, Target Price Projection
Alto Neuroscience,'s current and average target prices are 2.69 and 12.72, respectively. The current price of Alto Neuroscience, is the price at which Alto Neuroscience, is currently trading. On the other hand, Alto Neuroscience,'s target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Alto Neuroscience, Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Alto Neuroscience, Target Price
Follow Alto Neuroscience,'s market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.67 M.Market Cap |
|
Project Alto Neuroscience,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | 0.58 | 0.72 |
When accessing Alto Neuroscience,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Alto Neuroscience,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alto Neuroscience,'s profitability and make more informed investment decisions.
Evaluate Alto Neuroscience,'s management efficiency
Alto Neuroscience, has return on total asset (ROA) of (0.3236) % which means that it has lost $0.3236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5672) %, meaning that it created substantial loss on money invested by shareholders. Alto Neuroscience,'s management efficiency ratios could be used to measure how well Alto Neuroscience, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of March 2025, Return On Equity is likely to grow to 0.72, while Return On Tangible Assets are likely to drop (0.51). At this time, Alto Neuroscience,'s Non Current Assets Total are very stable compared to the past year. As of the 21st of March 2025, Other Current Assets is likely to grow to about 3.4 M, while Total Assets are likely to drop about 61 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (3.07) | (3.22) | |
| Tangible Book Value Per Share | (3.07) | (3.22) | |
| Enterprise Value Over EBITDA | (12.60) | (13.23) | |
| Price Book Value Ratio | (6.99) | (7.34) | |
| Enterprise Value Multiple | (12.60) | (13.23) | |
| Price Fair Value | (6.99) | (7.34) | |
| Enterprise Value | 435.5 M | 387.1 M |
The strategic initiatives led by Alto Neuroscience,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alto Neuroscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Etkin Amit over a month ago Acquisition by Etkin Amit of 215000 shares of Alto Neuroscience, at 4.2 subject to Rule 16b-3 | ||
Cox Christopher Nixon over two months ago Acquisition by Cox Christopher Nixon of 25236 shares of Alto Neuroscience, at 4.38 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 10681 shares of Alto Neuroscience, at 12.53 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 2931 shares of Alto Neuroscience, at 13.22 subject to Rule 16b-3 | ||
Alpha Wave Global Lp over a year ago Conversion by Alpha Wave Global Lp of 1962995 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Conversion by Chen Po Yu Jeff of 259 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Acquisition by Chen Po Yu Jeff of 30574 shares of ANRO subject to Rule 16b-3 | ||
Alkeon Capital Management Llc over a year ago ANRO exotic insider transaction detected |
Alto Neuroscience, Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 12th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify |
Alto Neuroscience, Earnings per Share Projection vs Actual
Alto Neuroscience, Corporate Management
| Melissa Berman | Vice Accounting | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jason Hoffman | Vice Resources | Profile | |
| Erin JD | General Officer | Profile |
Already Invested in Alto Neuroscience,?
The danger of trading Alto Neuroscience, is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alto Neuroscience, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alto Neuroscience,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alto Neuroscience, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alto Neuroscience, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alto Neuroscience,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alto Neuroscience, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alto Neuroscience, Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.